Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Fig. 3

Kaplan‒Meier curve of progression-free survival (PFS) according to heterogeneity determined by 18F-FES PET. A PFS predicted by interlesional heterogeneity, with patients stratified by the presence or absence of 18F-FES-negative lesions in the whole cohort. B PFS predicted by intralesional heterogeneity, with patients stratified by the median FES-HI in the subgroup cohort with only 18F-FES-positive lesions

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us